SUN PHARMA Fact Sheet, SUN PHARMA Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA Fact Sheet   (SUNP)


Update: Richa is Very Bullish on this Little-known Smallcap Stock


Here is the latest financial fact sheet of SUN PHARMA. For more details, see the SUN PHARMA quarterly results and SUN PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

SUN PHARMA Price History

Price Rs 828.0
Mkt Cap Rs m 1,986,529
Vol '000 212.0
P/E X 58.3
P/CF X 45.5
EPS (TTM) Rs 14.2
1 Day % -1.0
No. of shares m 2,399.34
1 Week % 2.9
1 Month % -8.4
1 Year % 22.4
52 week H/L Rs 966.9/664.1
As on Jun 28, 2022 (Close)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

SUN PHARMA Financials

No. of Mths
Year Ending
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
12
Mar-20
*
12
Mar-21
*
5-Yr Chart
Click to enlarge
SUN PHARMA EQUITY SHARE DATA
High Rs842701679484654 
Low Rs572433375315339 
Sales per share (Unadj.) Rs129.4109.8121.1136.9139.6 
Earnings per share (Unadj.) Rs32.710.713.417.49.5 
Diluted earnings per shareRs32.710.713.417.49.5 
Cash flow per share (Unadj.) Rs37.917.020.726.018.2 
Dividends per share (Unadj.) Rs3.502.002.754.007.50 
Adj. dividends per shareRs3.502.002.754.007.50 
Avg Dividend yield %0.50.40.51.01.5 
Book value per share (Unadj.) Rs152.7159.7172.6188.7193.6 
Adj. book value per shareRs152.7159.7172.6188.7193.6 
Shares outstanding (eoy) m2,399.262,399.322,399.342,399.342,399.34 
Bonus / Rights / Conversions  00000 
Price / Sales ratio x5.55.24.42.93.6 
Avg P/E ratio x21.753.039.422.952.1 
P/CF ratio (eoy) x18.633.425.515.427.3 
Price / Book Value ratio x4.63.53.12.12.6 
Dividend payout %10.718.720.622.978.8 
Avg Mkt Cap Rs m1,696,8771,360,0561,264,689958,8941,190,430 
No. of employees `000NANANANANA 
Total wages/salary Rs m49,02353,67159,67163,62468,622 
Avg. sales/employee Rs Th00000 
Avg. wages/employee Rs Th00000 
Avg. net profit/employee Rs Th00000 
SUN PHARMA INCOME DATA
Net Sales Rs m310,378263,416290,659328,375334,981 
Other income Rs m10,3029,12110,5946,5168,592 
Total revenues Rs m320,680272,537301,254334,891343,573 
Gross profit Rs m96,82245,84350,59367,13541,616 
Depreciation Rs m12,64814,99817,53320,52820,800 
Interest Rs m3,9985,1765,5533,0271,414 
Profit before tax Rs m90,47934,79038,10250,09627,994 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m12,1169,1106,0098,2285,147 
Profit after tax Rs m78,36325,67932,09341,86822,847 
Gross profit margin %31.217.417.420.412.4 
Effective tax rate %13.426.215.816.418.4 
Net profit margin %25.29.711.012.86.8 
SUN PHARMA BALANCE SHEET DATA
Current assets Rs m329,537316,359310,692316,542304,421 
Current liabilities Rs m178,870198,643173,396157,064161,456 
Net working cap to sales %48.544.747.248.642.7 
Current ratio x1.81.61.82.01.9 
Inventory Days Days67184148158149 
Debtors Days Days8510811210599 
Net fixed assets Rs m259,638304,731310,698334,230336,682 
Share capital Rs m2,3992,3992,3992,3992,399 
"Free" reserves Rs m363,971380,742411,691450,245462,229 
Net worth Rs m366,370383,141414,091452,645464,628 
Long term debt Rs m14,36117,72115,22620,2898,981 
Total assets Rs m589,174621,090621,389650,772641,103 
Interest coverage x23.67.77.917.520.8 
Debt to equity ratio x00000 
Sales to assets ratio x0.50.40.50.50.5 
Return on assets %14.05.06.16.93.8 
Return on equity %21.46.77.89.24.9 
Return on capital %24.810.010.211.26.2 
Exports to sales %00000 
Imports to sales %00000 
Exports (fob) Rs m00000 
Imports (cif) Rs m00000 
Fx inflow Rs m44,11851,40366,02574,21984,493 
Fx outflow Rs m24,48432,23338,61027,96430,334 
Net fx Rs m19,63419,17027,41546,25554,159 
SUN PHARMA CASH FLOW
From Operations Rs m 70,822 39,072 21,965 65,548 61,704 
From Investments Rs m -42,216 -33,708 -6,813 -25,888 5,362 
From Financial Activity Rs m -22,854 -15,393 -27,305 -57,151 -59,805 
Net Cashflow Rs m 6,107 -7,359 -8,442 -13,857 5,964 
* Results Consolidated
Source: Accord Fintech, Equitymaster

Share Holding

Promoters 54.5%
Institution 34.5%
Non-Institution 11.1%
Total 100.0%
Free Float 45.5%
Pledged promoter holdings 5.6%
Shareholding as on Mar 2022
 

Company Information

Regd Off Sun Pharma Advanced Research Centre (S P A R C), Tandalja, Vadodara - 390020
E-mail secretarial@sunpharma.com Web www.sunpharma.com
Tel 0265- 5515500 / 5515600 / 5515700 Fax 0265- 2354897
Sector PHARMACEUTICALS Group Sun Pharmaceutical Group
Tr Agent Link Intime India Pvt Ltd., C 101 247 Park, LBS Marg, Vikhroli (West)
Auditor Deloitte Haskins & Sells
CHM: Israel Makov COMP SEC: Anoop Deshpande YEAR OF INC: 1993 BSE CODE: 524715 FV (Rs): 1 DIV YIELD (%): 0.9

Read: SUN PHARMA 2020-21 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    AUROBINDO PHARMA    

Compare SUN PHARMA With:   CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    AUROBINDO PHARMA    


Yellow Ad

Advertisement

How to Find One Stock with Crorepati Potential?

There are three critical characteristics that differentiate a common stock from a potential 'crorepati' stock.

And we are going to reveal them during our 'One Stock Crorepati' MEGA summit on 30th June.

If you are interested in finding a potential 'crorepati' stock, don't miss this.

At this MEGA Summit we will reveal details of what we call a 'crorepati' stock...

You just cannot afford to miss this summit for anything.

Learn more



Today's Market

Sensex, Nifty Rebound from Day's Low to End Flat; IT & Auto Stocks Witness Buying(Closing)

Indian share markets witnessed a volatile trading session today as crude oil prices rebounded following last week's rout.

Views on news

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates (Views On News)

Jul 30, 2021

Here's a rundown on Sun Pharma's June quarter results.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks (Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Best Monopoly Stocks to Own in 2022 Views On News (Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

Is it Time to Start Buying Stocks Selectively? (Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

The One Smallcap Stock I'll Recommend Now (Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

When Will the Stock Market Recover? (Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUN PHARMA

SUN PHARMA - TEVA PHARMA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS